Oncolytics Biotech Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

San diego and calgary, ab , april 25, 2024 /prnewswire/ -- oncolytics biotech® inc. (nasdaq: oncy) (tsx: onc), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the acceptance of two abstracts at the 2024 american society of clinical oncology (asco) annual meeting, which is taking place from may 31 – june 4, 2024, in chicago, illinois. details on the abstracts and poster presentation are shown below.

Requested for q2 2024, the type c meeting is to focus on planned registration-enabling trial in hr+/her2- metastatic breast cancer overall survival results from the randomized hr+/her2- metastatic breast cancer bracelet-1 trial expected in h2 2024 san diego and calgary, ab , april 11, 2024 /prnewswire/ -- oncolytics biotech® inc. (nasdaq: oncy) (tsx: onc), a leading clinical-stage company specializing in immunotherapeutics for oncology, is pleased to announce the submission of a type c meeting request to the fda. this meeting aims to discuss the company's planned registration-enabling trial for pelareorep in hr+/her2- metastatic breast cancer (mbc).

San diego and calgary, ab , april 2, 2024 /prnewswire/ -- oncolytics biotech® inc. (nasdaq: oncy) (tsx: onc), a clinical-stage immunotherapeutics company focused on oncology, today announced that president and chief executive officer dr. matt coffey will participate in the viral approaches in oncology panel at canaccord genuity's horizons in oncology virtual conference, which is taking place on april 15, 2024. additional details on the panel presentation can be found below.

Pelareorep advancing to a registration-enabling study in 2024 in pancreatic cancer and expands pancreatic potential with new goblet cohort in combination with mfolfirinox impressive objective response rate in goblet study anal carcinoma cohort supports enrollment expansion expecting to report overall survival data from bracelet-1 breast cancer study in 2024 cash position of $34.9 million provides runway through critical milestones into 2025 management hosting conference call and webcast today at 4:30 p.m. et san diego and calgary, ab, march 7, 2024 /prnewswire/ -- oncolytics biotech® inc. (nasdaq: oncy) (tsx: onc), a clinical-stage immunotherapeutics company focused on oncology, today announced recent operational highlights and financial results for the fourth quarter and year ended december 31, 2023.

Us$5m grant supports study of pelareorep in combination with modified folfirinox +/- atezolizumab testing with the most common therapies could facilitate broad use of pelareorep in pancreatic cancer patients san diego and calgary, ab , march 5, 2024 /prnewswire/ -- oncolytics biotech® inc. (nasdaq: oncy) (tsx: onc), a clinical-stage immunotherapeutics company focused on oncology, today announced it has submitted an amendment to goblet to initiate a new phase 1/2 cohort evaluating pelareorep in combination with modified folfirinox (mfolfirinox) with and without atezolizumab (tecentriq®) in patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma (pdac). this amendment will be reviewed by the paul ehrlich institute (pei; germany's regulatory body) for approval before patient enrollment can begin.

Conference call and webcast to take place on Thursday, March 7, 2024, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB , March 4, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced that it will host a conference call and webcast on Thursday, March 7, 2024, at 4:30 p.m.

Oncolytics Biotech Inc. (NASDAQ:ONCY ) Q3 2023 Earnings Conference Call November 3, 2023 8:30 AM ET Company Participants Jon Patton - Director, IR Matt Coffey - President & CEO Thomas Heineman - Chief Medical Officer Andrew de Guttadauro - Global Head of Business Development, President, Oncolytics Biotech (U.S.) Inc. Kirk Look - CFO Conference Call Participants Louise Chen - Cantor John Newman - Canaccord Soumit Roy - JonesTrading Operator Good morning, and welcome to Oncolytics Biotech's Third Quarter 2023 Conference Call. All participants are now in listen-only mode.

Conference call and webcast to take place on Friday, November 3, 2023, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , Oct. 20, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced that it will host a conference call and webcast on Friday, November 3, 2023, at 8:30 a.m.

A handful of stocks to buy under $20 can offer investors explosive returns in uncertain market conditions. The article lists names that might not immediately grab headlines, but their strategic focus and innovative progressiveness qualify them as potential multi-baggers.

The heavy selling pressure might have exhausted for Oncolytics Biotech Inc. (ONCY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Oncolytics Biotech Inc. (NASDAQ:ONCY ) Q2 2023 Earnings Conference Call August 14, 2023 8:30 AM ET Company Participants Jon Patton - Director-Investor Relations and Communications Matt Coffey - President and Chief Executive Officer Thomas Heineman - Chief Medical Officer Andrew de Guttadauro - Global Head of Business Development, President, Oncolytics Biotech (U.S.) Inc. Kirk Look - Chief Financial Officer Conference Call Participants Patrick Trucchio - H.C. Wainwright Soumit Roy - JonesTrading John Newman - Canaccord Operator Good morning, and welcome to Oncolytics Biotech's Second Quarter 2023 Conference Call.

Conference call and webcast to take place on Monday, August 14, 2023, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , Aug. 4, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Monday, August 14, 2023, at 8:30 a.m.

Positive results achieved, in using pelareorep + paclitaxel for the treatment of HR+/HER2- metastatic breast cancer patients, in the phase 2 BRACELET-1 study. Preparation is underway to initiate a phase 3 study using pelareorep + paclitaxel for the treatment of HR+/HER2- metastatic breast cancer patients. The global breast cancer market size is expected to reach $85.5 billion by 2032; About 74% of all breast cancer are both HR-positive and HER2-negative.

The stock of Oncolytics Biotech Inc. ONCY, +23.25% soared 25% Thursday, after the San Diego-based company said its pelareorep therapy has been selected for inclusion in a an adaptive phase 3 pancreatic cancer clinical trial. An adaptive clinical trial is one which allows modifications to the trial or statistical procedures in the trial after it has been initiated.

Oncolytics Biotech Inc. (NASDAQ:ONCY ) Q1 2023 Earnings Conference Call May 5, 2023 8:30 AM ET Company Participants Jon Patton – Director-Investor Relations and Communications Matt Coffey – Chief Executive Officer Thomas Heineman – Chief Medical Officer Andrew de Guttadauro – Global Head of Business Development Kirk Look – Chief Financial Officer Conference Call Participants John Newman – Canaccord Louise Chen – Cantor Fitzgerald Patrick Trucchio – H.C. Wainwright Douglas Miehm – RBC Capital Markets Operator Good morning.